Osteogenesis imperfecta: questions and answers.

Area of Science:

• Genetics and molecular biology of rare bone disorders.
• Pediatric orthopedics and skeletal dysplasias.
• Pharmacological treatments for brittle bone disease.

Background:

• Osteogenesis imperfecta (OI) is a group of genetic disorders characterized by brittle bones.
• Recent advances have identified new genes associated with severe and recessive forms of OI.
• Current management involves bisphosphonates and orthopedic interventions, but optimal strategies are debated.

Purpose of the Study:

• To review and update the medical and orthopedic approaches to managing osteogenesis imperfecta in children.
• To discuss recent findings in the genetic basis, diagnosis, and treatment of OI.
• To highlight areas of ongoing research and clinical uncertainty.

Main Methods:

• Review of recent literature on osteogenesis imperfecta pathogenesis, diagnosis, and treatment.
• Analysis of new genetic discoveries, diagnostic methodologies, and therapeutic options.
• Synthesis of current evidence regarding bisphosphonate therapy and orthopedic interventions.

Main Results:

• Mutations in CRTAP and LEPRE1 genes explain some cases of OI previously lacking genetic identification.
• DNA analysis is currently considered superior to skin biopsy for OI diagnosis.
• Bisphosphonates are standard care, but evidence for fracture prevention and optimal treatment protocols (drug choice, duration) is limited.
• Intravenous and oral bisphosphonates show efficacy, but comparative data are scarce.

Conclusions:

• Genetic testing advancements are improving OI diagnosis, particularly for recessive forms.
• Further research is needed to establish evidence-based guidelines for bisphosphonate selection and treatment duration in pediatric OI.
• A multidisciplinary approach combining medical and orthopedic care is essential for optimizing outcomes in children with osteogenesis imperfecta.